Business · 04/04/2016Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for BRINTELLIX Patent Extension
Summary
The FDA has published a notice determining the regulatory review period for BRINTELLIX, a human drug product, following a submission to the USPTO for patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →